News | December 21, 2025
Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Prolia is a prescription medicine used to treat osteoporosis in women
Revenue increased 11.4 per cent to Rs. 8,545 crore
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
